Detecting Meaningful Change Using The North Star Ambulatory Assessment In Duchenne Muscular Dystrophy

Developmental Medicine and Child Neurology

Volumn 55, Issue 11, 2013, Pages 1046-1052

  Mayhew, Anna G ^a   Cano, Stefan J ^b   Scott, Elaine ^c,d   Eagle, Michelle ^a   Bushby, Kate ^a   Manzur, Adnan ^e   Muntoni, Francesco ^e  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d Muscular Dystrophy Campaign   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH STAR AMBULATORY ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DISABILITY EVALUATION; HUMANS; LINEAR MODELS; MALE; MULTICENTER STUDIES AS TOPIC; MUSCULAR DYSTROPHY, DUCHENNE; OUTCOME ASSESSMENT (HEALTH CARE); PREDNISOLONE;

EID: 84885183817     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/dmcn.12220     Document Type: Article

References (27)

1. Drousiotou A, Ioannou P, Georgiou T, et al. Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test 1998; 2: 55-60.
2. Emery AE. Population frequencies of neuromuscular diseases. I. Amyotrophic lateral sclerosis (motor neurone disease). Neuromuscul Disord 1991; 1: 323-5.
3. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77-93.
4. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008: CD003725.
5. Ricotti V, Ridout D, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2013; 84: 698-705.
6. Mazzone E, Martinelli D, Berardinelli A, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010; 20: 712-6.
7. Scott E, Eagle M, Mayhew A, et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 2012; 17: 101-9.
8. Mazzone ES, Messina S, Vasco G, et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 2009; 19: 458-61.
9. Mayhew A, Cano S, Scott E, et al. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 2011; 53: 535-42.
10. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8: 918-28.
11. Mazzone E, Vasco G, Sormani MP, et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 2011; 77: 250-6.
12. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000; 53: 459-68.
13. Lemieux J, Beaton DE, Hogg-Johnson S, Bordeleau LJ, Goodwin PJ. Three methods for minimally important difference: no relationship was found with the net proportion of patients improving. J Clin Epidemiol 2007; 60: 448-55.
14. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56: 395-407.
15. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999; 37: 469-78.
16. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27(Suppl.): S178-89.
17. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-15.
18. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 81-7.
19. Deyo RA, Inui TS. Toward clinical applications of health status measures: sensitivity of scales to clinically important changes. Health Serv Res 1984; 19: 275-89.
20. Muscular Dystrophy Campaign. (2013) Clinical Databases. http://www.muscular-dystrophy.org/how_we_help_you/for_professionals/clinical_databases (accessed 16 May 2013).
21. Hobart JC, Cano SJ, Thompson AJ. Effect sizes can be misleading: is it time to change the way we measure change? J Neurol Neurosurg Psychiatry 2010; 81: 1044-8.
22. Andrich D. Rating scales and Rasch measurement. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 571-85.
23. Andrich D, Sheridean B. RUMM2030. Perth, WA: Laboratory Pty Ltd, 1997-2012.
24. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006; 4: 70.
25. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-92.
26. Hobart J, Cano S. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess 2009; 13: iii.
27. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010; 9: 177-89.